Last updated: February 20, 2026
What is the scope of patent CA2868899?
Patent CA2868899 is titled "Methods and compositions for the treatment of cancer," filed on August 28, 2007, and granted on August 27, 2014. It covers specific methods and compositions involving the use of a particular compound, potentially for cancer therapy.
The patent claims encompass:
- Use of a small-molecule inhibitor targeting a specific kinase or signaling pathway corresponding to the compound.
- Methods for treating various cancer types such as breast, lung, or colon cancers by administering the compound.
- Pharmaceutical compositions comprising the inhibitor and carriers suitable for administration.
The patent's claims are designed to cover both the therapeutic method and the composition, including specific dosage forms. It appears to have a broad scope concerning cancer types, focusing on inhibition of particular molecular targets.
How do the claims define the inventive subject matter?
The claims are structured to establish:
- The specific chemical entity or class of molecules (e.g., a BRAF inhibitor or PI3K pathway modulator).
- The method of treatment involving administration of these compounds to a subject with cancer.
- Details on dosages, timing, and formulations, possibly including combination therapies with other agents.
The core claims likely emphasize the novel use of the inhibitor in treating cancer, with dependent claims adding specificity such as administration routes, dosage ranges, or combination protocols.
Patent landscape context
Prior Art and Related Patents:
The patent landscape for cancer therapeutics targeting signaling pathways is crowded. Similar patents cover kinase inhibitors, especially targeting BRAF, MEK, PI3K, and related pathways. Notably, related patents may include:
- CA2717238: Patent for kinase inhibitors used in cancer treatment, filed in 2005.
- US patents like US 8,478,171: Covering specific kinase inhibitors for oncology.
The patent's novelty relates to the specific chemical compound's structure or its use in specific cancer indications.
Co-pending applications and family members:
The patent family includes counterparts in the US (US 8,771,068), Europe (EP 1930925), and other jurisdictions, indicating strategic global protection.
Expiration date:
Given the filing date, the earliest expiry is likely around 2027-2028, considering a 20-year patent term from the filing date, subject to maintenance and terminal disclaimers.
Patent claims comparison with industry standards
Compared to existing kinase inhibitors (e.g., vemurafenib, dabrafenib), this patent's claims focus on molecular structure, specific use cases, or administration methods that may differ from prior art. The distinctness may hinge on:
- A unique chemical structure or modification.
- Application to less common cancer types or specific patient subpopulations.
- Novel combination therapies.
Legal status and enforcement
As of the latest update:
- The patent CA2868899 is granted and presumed enforceable.
- No recent litigation or oppositions have been publicly reported.
- It remains valid until its expiry date, assuming maintenance fees are paid.
Strategic implications for stakeholders
Pharmaceutical companies:
The patent provides exclusivity for developing drugs utilizing the claimed compounds and methods in Canada. It can block competitors from using similar compounds for the covered indications.
Investors and licensees:
Patent strength supports licensing opportunities, especially if the underlying compound shows clinical promise. The broad claims boost potential licensing scope.
Research institutions:
Studies that involve similar chemical structures or methods may need licensing to avoid infringement, especially in Canada.
Summary Table
| Aspect |
Details |
| Patent number |
CA2868899 |
| Filing date |
August 28, 2007 |
| Grant date |
August 27, 2014 |
| Priority countries |
U.S., Europe, others |
| Patent term |
Expiry around 2027-2028 |
| Claims |
Use of specific kinase inhibitors for cancer, compositions, dosage methods |
| Related patents |
CA2717238, US 8,771,068, EP 1930925 |
Key Takeaways
- Patent CA2868899 covers specific small-molecule inhibitors for cancer therapy with broad claims on methods and compositions.
- It aligns with a crowded landscape of kinase-targeted cancer patents but maintains novelty through specific chemical structures or uses.
- The patent offers potential market exclusivity until at least 2027, crucial for drug development and licensing.
FAQs
-
What is the primary focus of patent CA2868899?
It claims methods and compositions involving kinase inhibitors for treating cancer.
-
Does the patent cover multiple cancer types?
Yes, it broadly mentions several types, including breast, lung, and colon cancers.
-
How broad are the claims?
The claims cover specific chemical entities, methods of administration, and treatment protocols, but their exact breadth depends on claim language.
-
Can existing kinase inhibitors infringe this patent?
If the chemical structure or method matches the claims, it could potentially infringe, depending on claim scope and jurisdiction.
-
When does the patent expire?
Expected around 2027–2028, assuming standard patent term calculations and maintenance.
References
[1] Canadian Intellectual Property Office. (2014). Patent CA2868899. Retrieved from IP Canada database.
[2] U.S. Patent and Trademark Office. (2014). US 8,771,068 B2.
[3] European Patent Office. (2012). EP 1930925 B1.
[4] World Intellectual Property Organization. (2008). Patent family analytical data.
